Cocrystal Pharma, Inc. (COCP) - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc., a Delaware corporation, filed this Current Report on Form 8-K on May 15, 2025. The filing serves to announce the Company's results of operations for the fiscal quarter ended March 31, 2025. The Company's common stock trades on The Nasdaq Capital Market under the symbol "COCP."
Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results have been issued via a press release (Exhibit 99.1) but does not embed the financial data within the 8-K text itself.
Material Changes
The filing text does not provide details on material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The report explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Verify the specific financial results for the quarter ended March 31, 2025, by reviewing Exhibit 99.1 (Press Release) attached to this filing.
- Confirm the Company's cash position and burn rate, as these are critical for a pre-revenue or early-stage biopharma entity, though not listed in this summary text.
- Note that the financial data in the associated press release is not incorporated by reference into other SEC filings unless expressly stated.
- Review the full press release for any updates on clinical trial progress or regulatory milestones that may have driven the quarterly results.